Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Postmenopausal osteoporosis treatment industry 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug type trends
2.1.4 Route of administration trends
2.1.5 Distribution channel trends
Chapter 3 Postmenopausal Osteoporosis Treatment Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of osteoporosis among elderly woman population
3.2.1.2 Rising R&D and new drug approvals
3.2.1.3 Government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 Treatment compliance
3.2.2.2 Adverse effects of medications
3.2.3 Growth potential analysis
3.2.4 By drug type
3.2.5 By route of administration
3.2.6 By distribution channel
3.3 COVID-19 impact analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Drug Type, 2018-2032 (USD Million)
5.1 Key trends, by drug type
5.2 Bisphosphonates
5.3 Hormone replacement therapy (HRT)
5.4 Parathyroid hormone
5.5 Estrogen receptor modulators
5.6 Other drug types
Chapter 6 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)
6.1 Key trends, by route of administration
6.2 Oral
6.3 Parenteral
6.3.1.1 Intravenous
6.3.1.2 Intramuscular
6.3.1.3 Subcutaneous
6.4 Transdermal
6.5 Nasal
Chapter 7 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Million)
7.1 Key trends, by distribution channel
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies
Chapter 8 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Eli Lilly and Company
9.2 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
9.3 AbbVie company (Allergan Pharmaceuticals International Ltd.)
9.4 Amgen Inc.
9.5 Theramex(PAI and Carlyle)
9.6 Sun Pharmaceutical Industries Ltd.
9.7 Pfizer Inc.
9.8 Novartis AG
9.9 Mylan Inc.
9.10 Chugai Pharma China Co., Ltd. (Roche)
